JP2012516348A - ６−（５−クロロ−２−ピリジル）−５−［（４−メチル−１−ピペラジニル）カルボニルオキシ］−７−オキソ−６，７−ジヒドロ−５Ｈ−ピロロ［３，４−ｂ］ピラジンの被覆錠剤及びコーティングの効果を測定する方法 - Google Patents

６−（５−クロロ−２−ピリジル）−５−［（４−メチル−１−ピペラジニル）カルボニルオキシ］−７−オキソ−６，７−ジヒドロ−５Ｈ−ピロロ［３，４−ｂ］ピラジンの被覆錠剤及びコーティングの効果を測定する方法 Download PDF

Info

Publication number
JP2012516348A
JP2012516348A JP2011548294A JP2011548294A JP2012516348A JP 2012516348 A JP2012516348 A JP 2012516348A JP 2011548294 A JP2011548294 A JP 2011548294A JP 2011548294 A JP2011548294 A JP 2011548294A JP 2012516348 A JP2012516348 A JP 2012516348A
Authority
JP
Japan
Prior art keywords
composition
coating
oxo
carbonyloxy
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011548294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012516348A5 (enExample
Inventor
リチャード シア
トゥシャール ミスラ
コンスタンディノス サランテアス
フィリップ ボナシア
セイ グ ホァン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of JP2012516348A publication Critical patent/JP2012516348A/ja
Publication of JP2012516348A5 publication Critical patent/JP2012516348A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2011548294A 2009-01-30 2010-01-28 ６−（５−クロロ−２−ピリジル）−５−［（４−メチル−１−ピペラジニル）カルボニルオキシ］−７−オキソ−６，７−ジヒドロ−５Ｈ−ピロロ［３，４−ｂ］ピラジンの被覆錠剤及びコーティングの効果を測定する方法 Pending JP2012516348A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14862109P 2009-01-30 2009-01-30
US61/148,621 2009-01-30
PCT/US2010/022402 WO2010088385A1 (en) 2009-01-30 2010-01-28 Coated tablets of 6-(5-chloro-2-pyridyl) -5-[ (4-methyl-1-piperazinyl) carbonyloxy]-7-oxo-6, 7-dihydro-5h-pyrrol o [3,4-b] pyrazine and methods for measuring effectiveness of coating

Publications (2)

Publication Number Publication Date
JP2012516348A true JP2012516348A (ja) 2012-07-19
JP2012516348A5 JP2012516348A5 (enExample) 2013-02-07

Family

ID=42091495

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011548294A Pending JP2012516348A (ja) 2009-01-30 2010-01-28 ６−（５−クロロ−２−ピリジル）−５−［（４−メチル−１−ピペラジニル）カルボニルオキシ］−７−オキソ−６，７−ジヒドロ−５Ｈ−ピロロ［３，４−ｂ］ピラジンの被覆錠剤及びコーティングの効果を測定する方法

Country Status (7)

Country Link
US (2) US20100221338A1 (enExample)
EP (2) EP3632417A1 (enExample)
JP (1) JP2012516348A (enExample)
CN (2) CN104316631A (enExample)
AU (1) AU2010208240A1 (enExample)
CA (1) CA2750059C (enExample)
WO (1) WO2010088385A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026004941A1 (ja) * 2024-06-27 2026-01-02 日本臓器製薬株式会社 アルキン誘導体

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212036B2 (en) 2007-12-19 2012-07-03 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
CA2747008C (en) * 2007-12-19 2017-12-12 Richard Hsia Salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine
US8198278B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8269005B2 (en) 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-Oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8268832B2 (en) 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198277B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US20110009416A1 (en) * 2009-07-07 2011-01-13 Sepracor Inc. PH INDEPENDENT FORMULATIONS OF 6-(5-CHLORO-2-PYRIDYL)-5-[(4-METHYL-1-PIPERAZINYL)CARBONYLOXY]-7-OXO-6,7-DIHYDRO-5H-PYRROLO[3,4-b]PYRAZINE
CN103408967A (zh) * 2013-07-09 2013-11-27 吴江市冰心文教用品有限公司 一种天然可食用颜料
CN118069976B (zh) * 2024-03-11 2024-08-20 华中科技大学 一种老化sbs改性沥青双组分同步再生剂最佳掺量计算方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070098788A1 (en) * 2005-10-28 2007-05-03 Gore Subhash P Non-benzodiazepine hypnotic compositions
JP2009500425A (ja) * 2005-07-06 2009-01-08 セプラコア インコーポレーテッド エスゾピクロン及びトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−ｎ−メチル−１−ナフタレンアミン又はトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA04285A (fr) 1972-01-07 1979-12-31 Rhone Poulenc Sa Nouveaux dérivés de la pyrrolo (3,4-b) pyrazine et leur préparation.
AR208414A1 (es) 1974-11-07 1976-12-27 Rhone Poulenc Ind Procedimiento para obtener nuevos derivados de la((acil-4piperazinil-1)carboniloxi-5 pirrolinona-2)
US4543370A (en) * 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US5098715A (en) * 1990-12-20 1992-03-24 Burroughs Wellcome Co. Flavored film-coated tablet
FR2671800B1 (fr) 1991-01-17 1993-03-12 Rhone Poulenc Rorer Sa Derive de la 5h-pyrrolo[3,4-b]pyrazine optiquement actif, sa preparation et les compositions pharmaceutiques qui le contiennent.
US5786357A (en) 1991-12-02 1998-07-28 Sepracor Inc. Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone
AU3245593A (en) 1991-12-02 1993-06-28 Sepracor, Inc. Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (+) zopiclone
GB9401894D0 (en) * 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
US5733575A (en) * 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
US6451345B1 (en) * 2000-01-20 2002-09-17 Eurand Pharmaceuticals Ltd. Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration
EA200201044A1 (ru) * 2000-03-31 2003-04-24 Нюкомед Аустриа Гмбх Фармацевтическая композиция с контролируемым высвобождением, содержащая мидодрин и/или десглимидодрин
EP1465601A4 (en) * 2001-12-28 2006-02-15 Teva Pharma STABLE PHARMACEUTICAL FORMULATION OF PAROXETINE ANHYDROUS HYDROCHLORIDE AND PREPARATION METHOD
JP2007523165A (ja) * 2004-02-18 2007-08-16 セプレイコー インコーポレイテッド 睡眠の質を改善するためのドーパミン作動薬併用療法
CA2677470A1 (en) * 2004-04-05 2005-10-20 Sepracor Inc. Methods of treatment using eszopiclone
WO2006044202A2 (en) * 2004-10-19 2006-04-27 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid
US7476737B2 (en) * 2005-09-05 2009-01-13 Dr. Reddy's Laboratories Limited Eszopiclone process
AR056633A1 (es) * 2005-12-07 2007-10-17 Gador Sa Composiciones farmaceuticas de agentes hipnoticos de accion corta en forma de liberacion modificada y los procedimientos para preparar dichas formulaciones
US8309104B2 (en) * 2006-03-02 2012-11-13 Watson Pharmaceuticals, Inc. Oral controlled release formulation for sedative and hypnotic agents
US8268832B2 (en) * 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8212036B2 (en) * 2007-12-19 2012-07-03 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198278B2 (en) * 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8269005B2 (en) * 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-Oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198277B2 (en) * 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US20090269409A1 (en) * 2008-04-24 2009-10-29 Mukesh Kumar Garg Pharmaceutical compositions comprising eszopiclone

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009500425A (ja) * 2005-07-06 2009-01-08 セプラコア インコーポレーテッド エスゾピクロン及びトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−ｎ−メチル−１−ナフタレンアミン又はトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
US20070098788A1 (en) * 2005-10-28 2007-05-03 Gore Subhash P Non-benzodiazepine hypnotic compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026004941A1 (ja) * 2024-06-27 2026-01-02 日本臓器製薬株式会社 アルキン誘導体

Also Published As

Publication number Publication date
EP2391354A1 (en) 2011-12-07
CN102355892B (zh) 2014-10-22
CN104316631A (zh) 2015-01-28
EP3632417A1 (en) 2020-04-08
CN102355892A (zh) 2012-02-15
US20100221338A1 (en) 2010-09-02
CA2750059A1 (en) 2010-08-05
WO2010088385A1 (en) 2010-08-05
CA2750059C (en) 2014-11-18
US20140271858A1 (en) 2014-09-18
EP2391354B1 (en) 2019-11-27
AU2010208240A1 (en) 2011-09-22
US9114086B2 (en) 2015-08-25

Similar Documents

Publication Publication Date Title
US9114086B2 (en) Coated tablets of eszopiclone
AU2010277302B2 (en) Improved pharmacokinetics of S-Adenosylmethionine formulations
JP5869004B2 (ja) γ−ヒドロキシ酪酸の発泡性顆粒
ES2389223T3 (es) Formas de dosificación resistentes a la manipulación
JP6392207B2 (ja) シロドシンの苦味をマスキングした経口投与製剤
JP2007510733A (ja) プロトンポンプ阻害剤および睡眠剤の併用
CN107810006A (zh) 用于治疗失眠的组合物和方法
WO2018191482A2 (en) Methods of treating developmental encephalopathies
EP4007765A1 (en) Human squalamine derivatives, related compositions comprising the same, and methods of using the same
KR20210110585A (ko) 자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌
CN118267382A (zh) 用于痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗
KR20130099140A (ko) 베포타스틴 조성물
KR20110074604A (ko) 비만 세포 매개 질환의 치료를 위한 １-아미노-알킬시클로헥산 유도체
Mallik Pharmaceutical taste masking technologies of bitter drugs: a concise review
CA3094977A1 (en) Methods and compositions for treating hallucinations and conditions related to the same
Weidekamm et al. Lack of bioequivalence of a generic mefloquine tablet with the standard product
CN115397425A (zh) 使用曲匹地尔治疗认知障碍
CN109846843A (zh) 地氯雷他定口腔崩解片
Modi et al. E-tongue: an outstanding device in pharmaceutical taste detector of taste masked bitter drugs
WO2023122469A2 (en) Implants for loss of taste and smell
Modi et al. Novel Electronic Taste Detector for Taste Masked Bitter Drugs: Emerging Approach to E-Taster
EP4452274A2 (en) Gel treatment for loss of taste and smell
WO2024234014A1 (en) Sublingual spray formulations of psychedelics
Gajendran Performance testing of medicated chewing gums with the goal of establishing in vitro in vivo correlation
CN103864628A (zh) 一种盐酸氨溴索化合物及口腔崩解片

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140523

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140825

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150317